Intravenous Recombinant Human Prourokinase (rhPro-UK) for Acute Ischemic Stroke Within 4.5 to 24 Hours of Onset
Key facts
- Who runs it
- Tasly Biopharmaceuticals Co., Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 978 people, planned
- Starts
- 30 Nov 2026
- Expected to end
- 1 Jun 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Recombinant Human Prourokinase for Injection (rhPro-UK)
- Aspirin Enteric-Coated Tablets
- Aspirin Enteric-Coated Tablet Placebo
- rhPro-UK Placebo
- Record updated
- 17 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (35)Hide the full registry criteria
Who can take part
- Age >=18 years, male or female
- Time from stroke symptom onset to planned thrombolysis >4.5 hours and <=24 hours (including wake-up stroke and unwitnessed stroke); the time of symptom onset is defined as the time the patient was last known to be well
- Proximal or distal occlusion/stenosis of the internal carotid artery, middle cerebral artery, anterior cerebral artery, or posterior cerebral artery confirmed by CTA or MRA, identified as the culprit vessel responsible for the current acute ischemic stroke
- Salvageable ischemic tissue demonstrated on CT perfusion (CTP) or MRI PWI/DWI sequences (infarct core volume <70 mL; hypoperfusion-to-infarct core mismatch ratio >=1.8; mismatch volume >=15 mL)
- NIHSS score of 6 to 25 (inclusive)
- Pre-stroke mRS score <2
- No significant improvement in stroke clinical manifestations before treatment (as assessed by the investigator)
- The patient or his/her legally authorized representative is willing to participate in the trial and agrees to sign the informed consent form
Who cannot take part
- Previous history of intracranial hemorrhage
- Intracranial or intraspinal surgery within the past 3 months
- Major surgery or severe trauma within the past 2 weeks (as assessed by the investigator)
- Treatment with low-molecular-weight heparin or heparin within 24 hours
- Use of thrombin inhibitors or factor Xa inhibitors within the past 48 hours
- Known hypersensitivity to rhPro-UK, the active ingredient of aspirin, or any other components of the investigational products
- Intracranial hemorrhage shown on CT/MRI (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma, etc.)
- Major head trauma or ischemic stroke within the past 3 months
- Gastrointestinal or urinary tract bleeding within the past 3 weeks
- Active internal bleeding
- Hypertension remaining uncontrolled despite active antihypertensive therapy, with a post-treatment systolic blood pressure still >185 mmHg or diastolic blood pressure still >110 mmHg
- Seizure at stroke onset, or coexisting psychiatric disorder precluding compliance
- Severe hepatic insufficiency, including liver failure, cirrhosis, portal hypertension (esophageal varices), or active hepatitis
- Any terminal illness with a life expectancy of less than 1 year
- Any condition that, in the opinion of the investigator, makes the patient unsuitable for participation in the trial
- Acute bleeding tendency, including platelet count <100 x 10\^9/L
- Currently taking oral anticoagulants with prothrombin time (PT) >15 seconds or international normalized ratio (INR) >1.7
- Blood glucose <2.8 mmol/L (50 mg/dL) or >22.2 mmol/L (400 mg/dL)
- Severe renal insufficiency (eGFR <30 mL/min/1.73 m\^2)
- Unable to complete CTP/CTA or PWI/DWI/MRA examination
- Large cerebral infarction indicated by CT/MRI (infarct area larger than one-third of the middle cerebral artery territory)
- Intracranial tumor or giant intracranial aneurysm
- Arterial puncture at a non-compressible site within the past 1 week
- Aortic arch dissection
- Bacterial endocarditis or pericarditis
- Pregnant or lactating women
- Participation in another clinical trial within the past 1 month
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Acute ischemic stroke AIS
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This is a multicenter, randomized, double-blind, double-dummy, standard-of-care-controlled Phase III clinical trial to evaluate the efficacy and safety of intravenous recombinant human prourokinase (rhPro-UK) in adult patients with acute ischemic stroke (AIS) within 4.5 to 24 hours of symptom onset, including wake-up stroke and unwitnessed stroke.Eligible patients with salvageable ischemic tissue confirmed by CT perfusion or MRI perfusion/diffusion imaging will be randomized in a 1:1 ratio to receive either intravenous rhPro-UK 35 mg plus oral aspirin enteric-coated tablet placebo, or intravenous rhPro-UK placebo plus oral aspirin enteric-coated tablets 100-300 mg (standard of care).The primary objective is to evaluate the efficacy of intravenous rhPro-UK compared with standard of care in achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0-1 at 90 days after treatment. A total of 978 participants (489 per arm) will be enrolled at multiple centers in China.
The 2 groups in the trial
- rhPro-UK GroupTreatment being tested
Participants receive an intravenous infusion of recombinant human prourokinase (rhPro-UK) 35 mg in normal saline (15 mg administered as a slow intravenous bolus over 3 minutes, followed by the remaining 20 mg administered by intravenous infusion/pump over the subsequent 30 minutes), plus oral aspirin enteric-coated tablet placebo 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.
Treatment: Recombinant Human Prourokinase for Injection (rhPro-UK) and Aspirin Enteric-Coated Tablet Placebo
- Standard of Care (SOC) GroupExisting treatment, for comparison
Participants receive an intravenous infusion of rhPro-UK placebo in normal saline (same administration regimen as the rhPro-UK group), plus oral aspirin enteric-coated tablets 100-300 mg (at the investigator's discretion) at the start of thrombolysis. All investigational products are administered once only.
Treatment: Aspirin Enteric-Coated Tablets and rhPro-UK Placebo
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Randomized, Double-Blind, Double-Dummy, Standard-of-Care-Controlled Phase III Clinical Trial of Intravenous Recombinant Human Prourokinase (rhPro-UK) for the Treatment of Acute Ischemic Stroke Within 4.5 to 24 Hours of Symptom Onset
- Criteria questions
- Built from NCT07942584, who can take part
- Record updated
- 17 November 2026